Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: A double-blind, placebo-controlled study

International Archives of Allergy and Immunology

Volumn 142, Issue 3, 2007, Pages 239-246

  Vervloet, D ^a   Birnbaum, J ^a   Laurent, P ^b   Hugues, B ^b   Fardeau, M F ^b   Massabie Bouchat, Y P ^b   Aferiat Derome, A ^b   Andre C ^c,d  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Scientific and Medical Department ^*

^c Scientific Department   (France)

^d Stallergenes SA   (France)

Author keywords

Cypress; Immunotherapy, sublingual; Juniperus ashei; Rhinoconjunctivitis; Rush

Indexed keywords

ANTIBODY; CORTICOSTEROID; EYE DROPS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; JUNIPERUS ASHEI ALLERGEN EXTRACT; LORATADINE; PLACEBO; POLLEN ANTIGEN; PREDNISOLONE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVITIS; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUPRESSUS; CUPRESSUS ARIZONICA; CUPRESSUS SEMPERVIRENS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR PRURITUS; ECZEMA; FEMALE; FRACTURE; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL PRURITUS; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOCONJUNCTIVITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STOMACH PAIN; SWALLOWING; SYMPTOMATOLOGY; THORAX PAIN; TONGUE DISEASE; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 33847050777     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097026     Document Type: Article

References (39)

1. Birnbaum J, Ramadour M, Magnan A, Vervloet D: Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003;33:58-64.
2. Bousquet J, Hejjaoui A, Skassa-Brociek W, Guérin B, Maasch HJ, Dhivert H, Michel FB: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-598.
3. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797-802.
4. Harvey SM, Laurie S, Hilton K, Khan DA: Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004;92:414-419.
5. Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz AB, Schnitker J, Mann W: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999;103:47-53.
6. Tabar AI, Muro MD, Garcia BE, Alvarez MJ, Acero S, Rico P, Olaguibel JM: Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. Invest Allergol Clin Immunol 1999;9:155-164.
7. Parmiani S, Tavora LF, Moreno C, Guardia P, Rico P: Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol 2002;30:283-291.
8. Wilson DR, Torres Lima M, Durham SR: Sublingual Immunotherapy for Allergic Rhinitis (Cochrane Review). Oxford, The Cochrane Library, 2003, issue 2 (update software).
9. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling H-J: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45-53.
10. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio P: Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995;23:224-230.
11. Purello D'Ambrosio F, Ricciardi L, Isola S, Puccinelli P, Musarra A: Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol 1996;24:146-151.
12. Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, Parmiani S: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001;29:103-110.
13. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, Canonica GW: Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999;104:964-968.
14. Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabié-Bouchat YP, Aferiat-Derome A, Vatrinet C, André C: Safety and clinical efficacy of rush sublingual cypress immunotherapy: preliminary results. Allergy 2002;57(suppl 73):70.
15. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G: Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006;139:149-152.
16. Gammeri E, Arena A, D'Anneo R, La Grutta S: Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:221-223.
17. Rossi RE, Monasterolo G, Coco G, Operti D: Possible relationship between systemic side-effects and sensitization to r Par j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol 2005;138:105-110.
18. Hrabina M, Dumur JP, Sicard H, Viatte A, André C: Diagnosis of cypress pollen allergy: in vivo and in vitro standardization of a Juniperus ashei pollen extract. Allergy 2003;58:808-813.
19. Arilla MC, Ibarrola I, Martinez A, Asturias JA: Quantification assay for the major allergen of Cupressus sempervirens pollen, Cup s 1, by sandwich ELISA. Allergol Immunopathol 2004;32:319-325.
20. Mari A, Di Felice G, Afferni C, Barletta B, Tinghino R, Sallustro F, Pini C: Assessment of skin prick test and serum specific IgE detection in the diagnosis of Cupressaceae pollinosis. J Allergy Clin Immunol 1996;98:21-31.
21. Di Felice G, Barletta B, Tinghino R, Pini C: Cupressaceae pollinosis: identification, purification and cloning of relevant allergens. Int Arch Allergy Immunol 2001;125:280-289.
22. Malling H-J, Weeke B: Immunotherapy (position paper). EAACI Immunotherapy Subcommittee. Allergy 1993;48:3-35.
23. Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol 1990;18:277-284.
24. André C, Vatrinet C, Galvain S, Carat F, Sicard H: Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:2229-2234.
25. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, Basset D, Fadel R, André C: Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002;129:248-253.
26. Coopman SA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674.
27. Kletzel M, Beck S, Elser J, Shock N, Burks W: Trimethoprim- sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991;145:1428-1429.
28. Gluckstein D, Ruskin J: Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849-853.
29. Kalanadhabhatta V, Muppidi D, Sahni H, Robles H, Kramer M: Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired human immunodeficiency virus-infected syndrome. Ann Allergy Asthma Immunol 1996;77:394-400.
30. Miller FF, Smith RE, Lanson WJ: Repository emulsion therapy for mountain cedar pollinosis: a double-blind study. J Allergy 1964;35:7-11.
31. Pence HL, Mitchell DQ, Greely RL et al: Immunotherapy for mountain cedar pollinosis. A double-blind study. J Allergy Clin Immunol 1976;58:39-50.
32. Fling JA, Ruff ME, Parker WA, et al: Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101-109.
33. Parker W, Whisman B, Apaleski S, et al: The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84:667-677.
34. Ariano R, Panzani RC, Augeri G: Double-blind, placebo-controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol Immunopathol 1997;25:23-29.
35. Ito Y, Takahashi Y, Fujita T, et al: Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollinisation. Auris Nasus Larynx 1977;24:163-170.
36. Clavel R, Bousquet J, André C: Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493-498.
37. Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Report: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:1-334.
38. André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M: A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003;131:118.
39. André C, Dumur JP, Hrabina M, Lefebvre E, Sicard H: Juniperus ashei: le golden standard des cupressacées. Allergie Immunol 2000;32:104-106.